Cargando…

Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk

EGFR is a potential therapeutic target for treating bladder cancer, but has not been approved for clinical use yet. Metformin is a widely used antidiabetic drug and has demonstrated interesting anticancer effects on various cancer models, alone or in combination with chemotherapeutic drugs. The effi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Mei, Huang, Yanjun, Tao, Ting, Peng, Cai-Yun, Su, Qiongli, Xu, Wanjun, Darko, Kwame Oteng, Tao, Xiaojun, Yang, Xiaoping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917871/ https://www.ncbi.nlm.nih.gov/pubmed/27334428 http://dx.doi.org/10.1038/srep28611

Ejemplares similares

Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
por: Huang, Yanjun, et al.
Publicado: (2018)

A novel synthetic derivative of quercetin, 8-trifluoromethyl-3,5,7,3′,4′-O-pentamethyl-quercetin, inhibits bladder cancer growth by targeting the AMPK/mTOR signaling pathway
por: Tao, Ting, et al.
Publicado: (2017)

Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
por: Li, Ling, et al.
Publicado: (2020)

Down‐regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer
por: Su, Qiongli, et al.
Publicado: (2018)

High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model
por: Peng, Mei, et al.
Publicado: (2016)

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
por: Pan, Yong-hong, et al.
Publicado: (2018)

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
por: He, Peng, et al.
Publicado: (2013)

Protective effects of metformin in various cardiovascular diseases: Clinical evidence and AMPK‐dependent mechanisms
por: Bu, Yizhi, et al.
Publicado: (2022)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation
por: Cho, Jung Hee, et al.
Publicado: (2018)

Docosahexaenoic Acid Serving As Sensitizing Agents And Gefitinib Resistance Revertants In EGFR Targeting Treatment
por: Ding, Xuansheng, et al.
Publicado: (2019)

Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms
por: Chen, Suet Ching, et al.
Publicado: (2017)

ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells
por: Qi, Mengfan, et al.
Publicado: (2018)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer
por: Ren, Hui, et al.
Publicado: (2019)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells
por: Cruz Da Silva, Elisabete, et al.
Publicado: (2021)

Metformin selectively dampens the acute inflammatory response through an AMPK-dependent mechanism
por: Postler, Thomas S., et al.
Publicado: (2021)

Metformin attenuates the D-galactose-induced aging process via the UPR through the AMPK/ERK1/2 signaling pathways
por: Cai, Hua, et al.
Publicado: (2020)

Metabolic regulation by the intestinal metformin-AMPK axis
por: Zhang, Song-Yang, et al.
Publicado: (2022)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Daidzein Synergizes with Gefitinib to Induce ROS/JNK/c-Jun Activation and Inhibit EGFR-STAT/AKT/ERK Pathways to enhance Lung Adenocarcinoma cells chemosensitivity
por: Mhone, Thomas Gabriel, et al.
Publicado: (2022)

Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study
por: Murray, Samuel, et al.
Publicado: (2010)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations
por: Song, Ruiqiang, et al.
Publicado: (2022)

Metformin induces pyroptosis in leptin receptor-defective hepatocytes via overactivation of the AMPK axis
por: Liu, Bingli, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Cooperative Assembly of a Protein-DNA Filament for Nonhomologous End Joining
por: Tsai, Chun J., et al.
Publicado: (2013)

Will Joining Cooperative Promote Farmers to Replace Chemical Fertilizers with Organic Fertilizers?
por: Wei, Guangcheng, et al.
Publicado: (2022)

The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective
por: Agius, Loranne, et al.
Publicado: (2020)

Demystifying the Relationship Between Metformin, AMPK, and Doxorubicin Cardiotoxicity
por: Singh, Manrose, et al.
Publicado: (2022)

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
por: Douillard, Jean-Yves, et al.
Publicado: (2014)

Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death
por: Britain, Colleen M., et al.
Publicado: (2018)

Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway
por: Li, Li, et al.
Publicado: (2015)

Metformin attenuates osteoclast-mediated abnormal subchondral bone remodeling and alleviates osteoarthritis via AMPK/NF-κB/ERK signaling pathway
por: Guo, Haohui, et al.
Publicado: (2021)

Metformin suppresses foam cell formation, inflammation and ferroptosis via the AMPK/ERK signaling pathway in ox‑LDL‑induced THP‑1 monocytes
por: Zhao, Yihan, et al.
Publicado: (2022)

Metformin Inhibits Expression and Secretion of PEDF in Adipocyte and Hepatocyte via Promoting AMPK Phosphorylation
por: Yang, Shumin, et al.
Publicado: (2013)

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
por: Xin, Shuang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r6q08mi033soubjcn5rgjpcnc3